About Organon
Organon is a publicly listed company based in Jersey City (United States), and was acquired by Sun Pharma in April 2026. Organon is focused on improving womens health globally. It operates on a Direct-to-Consumer (D2C) and Professional Services model. Organon has completed 4 acquisitions, including Alydia Health, Dermavant and Forendo Pharma. Organon offers products and services including Women's Health Solutions, Biosimilars, and Established Brands. Its focus areas include Pharmaceuticals, Women's Health, Biotechnology and Biosimilars. Its legal entity is Organon Denmark ApS. Its competitors include Roivant Sciences, Gilead and Lilly; 1 of its 3 listed competitors has raised funding.
Company details
Organon is dedicated to advancing womens health through a diverse portfolio of over 70 medicines and devices. Focus areas include reproductive health, maternal conditions, and contraception, alongside biosimilars and established brands in cardiovascular, neurology, and dermatology sectors. Therapies are delivered to over 140 markets worldwide, addressing conditions unique to women or affecting them disproportionately. Solutions are developed to support women at all life stages, ensuring accessible healthcare options for patients and providers.
- Annual Revenue$6.22 B (USD)-2.92as on Dec 31, 2025
- Net Profit$187 M (USD)-78.36as on Dec 31, 2025
- EBITDA$1.64 B (USD)-7.83as on Dec 31, 2025
- InvestorsMerck
& 1 more
- Investments & AcquisitionsAlydia Health
& 3 more
- Acquired by
Products & Services of Organon
Organon offers a comprehensive portfolio of products and services, including Women's Health Solutions, Biosimilars, and Established Brands.
Solutions for women's reproductive and maternal health are provided.
Accessible treatment options through biosimilars are made available.
Therapies for various conditions like cardiovascular are offered.
Apps and channels of Organon
its YouTube channel Organon has 476 subscribers and 30 videos.
Videos from Organon
The most watched videos on Organon's YouTube channel, Organon (476 subscribers). Click a video to play it here.
More on Organon.
Investors in Organon
Organon has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Merck and Sun Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | merck.com | Kenilworth, United Kingdom | |
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | sunpharma.com | Mumbai, India |
Investor details for Organon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Organon
337 people are tracked at Organon (206 in leadership, 10 in board & advisors, 121 in team).
| Name | Role | Group |
|---|---|---|
Damien Morris | Associate Director Of Finance External Manufacturing | Leadership |
Charlotte Owens | Head of Medical Affairs & Outcomes Research | Leadership |
Sara Dean | Global Director, Medical Affairs - Contraception Strategy | Leadership |
Mostafa Taha | Global Director Commercial Trade Channels | Leadership |
Eddie Yu | Director, Finance - Above Market Accounting | Leadership |
Leanne Miller | Associate Director, Customer Experience & Commercial Acceleration | Leadership |
Sadia Khan | Director Fp&a And Strategy | Leadership |
Nadim Hawwari | SCM & Integration Finance Associate Director | Leadership |
Therry Engelen | Associate Director / Operations Lead | Leadership |
Wayne Chen | Executive Director, Translational Medicine And Early Clinical Development Lead | Leadership |
Julie Pentz | Chief Procurement Officer | Leadership |
Rijesh Shrestha | Director, Transfer Pricing | Leadership |
Glenn Coleman | Associate Director, Business Technology Processes & Governance | Leadership |
Rachel Stahler | Chief Digital & Growth Officer | Leadership |
Subhajit Singha | Associate Director - Enterprise Data & Analytics Platform | Leadership |
Sloan Tandet | Associate Director, Market Research Global Commercial Insights & Analytics | Leadership |
Samantha Bruno | Director | Leadership |
Wendy Wocher | Associate Director Business/tech. Analysis | Leadership |
Julia Luftmann | Associate Director, Compliance & Operations - Global Business Insights And Analytics | Leadership |
Lauren Caruso Davis | Associate Director Brand Analytics | Leadership |
317 more people are available in the full profile.
Complete people profiles for Organon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Organon
Organon is a publicly listed company on the NYSE with ticker symbol OGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 May 2021
- Listed onNYSE: OGN
- Listed entityOrganon & Co.
- Exchange sectorHealth technology
- ISINUS68622V1061
- Share price$13.77 · 2026-10-13
- Market capitalisation$3.62B
- Price to earnings17.6
- EPS (diluted, trailing year)$0.78
- Dividend yield0.58%
- Volume (last session)2,893,105
Financials of Organon
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $6.22B | $187.0M | $1.64B |
| 2024 | $6.40B | $864.0M | $1.77B |
| 2023 | $6.26B | $1.02B | $1.56B |
| 2022 | $6.17B | $917.0M | $1.93B |
| 2021 | $6.36B | $1.35B | $2.07B |
Detailed financial statements for Organon
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Organon
Organon has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Alydia Health, Dermavant and Forendo Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecule therapeutics for inflammatory skin diseases are developed. | dermavant.com | Phoenix, United States | 2016 | Sep 2024 | $1.2B | |
Small molecule therapeutics for reproductive health are developed. | forendo.com | Turku, Finland | 2013 | Nov 2021 | $75M | |
Medical devices for postpartum hemorrhage treatment are developed. | alydiahealth.com | Menlo Park, United States | 2010 | Mar 2021 | $215M | |
Postpartum hemorrhage is controlled via vacuum-induced uterine contraction devices. | thejadasystem.com | San Mateo, United States | 2020 | Mar 2021 | $240M |
Complete acquisition details for Organon
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Organon
7 dated milestones of Organon across 19 years, from founding to its latest funding, stage changes and deals.
- Exit Acquired by Merck.
- Acquisition Acquires The JADA System.
- Acquisition Acquires Alydia Health.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Forendo Pharma.
- Acquisition Acquires Dermavant.
- Exit Acquired by Sun Pharma.
Competitors of Organon
Organon has 3 listed competitors in our database, 1 of them funded. They include Roivant Sciences, Gilead and Lilly.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| gilead.com | 1987 | Foster, United States | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | ||
| lilly.com | 1876 | United States | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. |
Detailed competitors of Organon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Organon
Websites that share an audience with Organon (organon.com).
Websites whose visitors overlap most with Organon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bauschhealth.com | 100% | 32.2K | #988,502 | View details | |
| henlius.com | 95% | 25K | #1,127,187 | View details | |
| formatech.com | 91% | View details | |||
| stridesarco.com | 90% | View details | |||
| mn.com.tr | 82% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Organon
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Women's Health & Fertility
3 companies that operate in the same segment as Organon (Women's Health & Fertility) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of cell-free DNA testing for oncology, women’s health, and organ health | 2004 | Redwood City, California, United States | USD 152.1 M | USD 2.31 B | 4,430 | |
Therapeutics for women's healthcare are developed and offered. | 1997 | Princeton, New Jersey, United States | USD 123.06 M | USD 19.59 M | ||
Provider of cell-free cancer liquid biopsy test | 2015 | San Francisco, California, United States | USD 388.62 M | 861 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Organon
Complete news archive for Organon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Organon
Organon is headquartered in Jersey City, United States. It is registered at Jersey City, New Jersey, United States.
Annual revenue of Organon is $6.22B as on Dec 31, 2025.
Organon is dedicated to advancing womens health through a diverse portfolio of over 70 medicines and devices. Focus areas include reproductive health, maternal conditions, and contraception, alongside biosimilars and established brands in cardiovascular, neurology, and dermatology sectors. Therapies are delivered to over 140 markets worldwide, addressing conditions unique to women or affecting them disproportionately. Solutions are developed to support women at all life stages, ensuring accessible healthcare options for patients and providers.
Organon's top competitors include Roivant Sciences, Lilly and Gilead.
Organon offers Women's Health Solutions, Biosimilars, and Established Brands.
Yes, Organon is publicly traded on NYSE under the ticker symbol OGN.
Organon has made 4 acquisitions, including Alydia Health, Dermavant, and Forendo Pharma.
Organon has 2 investors. Key investors include Merck, and Sun Pharma.
Organon operates through Organon Denmark Aps.
Yes. Organon was acquired by Merck in November 2007.

